Loading clinical trials...
Loading clinical trials...
The primary objective of this study is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of CHIR-258 when administered to subjects with refractory or rela...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Novartis
NCT07249528 · Non-hodgkin Lymphoma, Multiple Myeloma
NCT06215118 · Multiple Myeloma
NCT06679101 · Multiple Myeloma, Newly Diagnosed Multiple Myeloma
NCT05969860 · Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, and more
NCT06870760 · Clonal Hematopoiesis of Indeterminate Potential, Monoclonal Gammopathy, and more
Mayo Clinic - Arizona
Scottsdale, Arizona
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Emory University
Atlanta, Georgia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions